Jason Haldas, MD

Current Trials

• Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

  HIC ID2000029793RoleSub InvestigatorPrimary Completion Date02/01/2023

  Recruiting Participants

  Lymphoma

• A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma

  HIC ID2000026850RoleSub InvestigatorPrimary Completion Date12/31/2024

  Recruiting Participants

  Gynecological Cancers

• Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

  HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033

  Recruiting Participants

  Prostate Cancer

• Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

  HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026

  Recruiting Participants

  Lung Cancer

• An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)

  HIC ID2000025449RoleSub InvestigatorPrimary Completion Date10/30/2023

  Recruiting Participants

  Breast Cancer